- Report
- October 2024
- 193 Pages
Global
From €3280EUR$3,545USD£2,758GBP
€3644EUR$3,939USD£3,065GBP
- Report
- March 2025
- 175 Pages
Global
From €4154EUR$4,490USD£3,493GBP
- Report
- February 2025
- 200 Pages
Global
From €4154EUR$4,490USD£3,493GBP
- Report
- February 2025
- 200 Pages
Global
From €4154EUR$4,490USD£3,493GBP
- Drug Pipelines
- April 2025
- 60 Pages
Global
From €1388EUR$1,500USD£1,167GBP
- Report
- May 2024
- 137 Pages
Global
From €6012EUR$6,499USD£5,056GBP
- Report
- May 2024
- 138 Pages
Global
From €6012EUR$6,499USD£5,056GBP
- Report
- August 2022
- 120 Pages
Global
From €4394EUR$4,750USD£3,695GBP
- Report
- May 2023
- 103 Pages
Global
From €3500EUR$4,053USD£3,047GBP
- Report
- May 2025
- 50 Pages
Global
From €2451EUR$2,650USD£2,062GBP
Zoledronic acid is a drug used to treat endocrine and metabolic disorders. It is a bisphosphonate, a type of drug that helps to reduce the activity of cells that break down bone. Zoledronic acid is used to treat conditions such as osteoporosis, Paget's disease, and hypercalcemia. It is also used to reduce the risk of fractures in people with osteoporosis. Zoledronic acid works by slowing down the activity of cells that break down bone, which helps to reduce bone loss and increase bone density.
Zoledronic acid is available in both oral and intravenous forms. The intravenous form is usually given as an infusion over a period of 15 minutes. The oral form is taken as a tablet once a day. Common side effects of zoledronic acid include nausea, vomiting, and diarrhea.
Companies in the zoledronic acid market include Novartis, Amgen, Merck, and Teva Pharmaceuticals. Show Less Read more